Two Sigma Advisers LP Sells 74,300 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Two Sigma Advisers LP lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 913,500 shares of the biopharmaceutical company's stock after selling 74,300 shares during the quarter. Two Sigma Advisers LP owned about 0.99% of Ultragenyx Pharmaceutical worth $38,431,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. Van ECK Associates Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 273 shares during the last quarter. BOKF NA increased its holdings in shares of Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after purchasing an additional 382 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares during the period. Arizona State Retirement System grew its holdings in Ultragenyx Pharmaceutical by 2.4% during the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock worth $1,011,000 after acquiring an additional 568 shares during the period. Finally, Guggenheim Capital LLC grew its holdings in Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Guggenheim Capital LLC now owns 45,222 shares of the biopharmaceutical company's stock worth $1,902,000 after acquiring an additional 670 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on RARE shares. JPMorgan Chase & Co. increased their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Finally, Morgan Stanley lifted their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $90.93.

Ultragenyx Pharmaceutical Trading Up 0.4%

RARE stock traded up $0.15 during trading on Friday, hitting $35.66. The company had a trading volume of 441,516 shares, compared to its average volume of 826,659. The company has a market cap of $3.37 billion, a P/E ratio of -5.62 and a beta of 0.34. The company has a fifty day moving average price of $36.05 and a two-hundred day moving average price of $41.18. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.03) EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at $2,358,014.08. This represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Richard Pinion sold 14,439 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the transaction, the insider now directly owns 107,766 shares of the company's stock, valued at $4,536,948.60. This trade represents a 11.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.